International Flavors & Fragrances Inc. (IFF) 2025 Annual Report: Navigating Challenges and Pursuing Growth

The decline in total sales was significantly influenced by divestitures and foreign currency exchange rates, with divestitures alone contributing approximately $757 million to the downturn. The company’s gross profit decreased by $186 million to $3.938 billion, resulting in a gross margin of 36.2% of sales, compared to 35.9% in the prior year. This slight improvement in gross margin reflects operational efficiencies and volume increases across several segments.

IFF's income statement revealed a troubling net loss of $361 million for 2025, a stark contrast to the net income of $243 million in 2024. The operating income also turned negative at -$382 million, primarily due to increased operating expenses and significant impairment charges related to divestitures.

IFF operates through five reportable segments: Taste, Food Ingredients, Health & Biosciences, Scent, and the now-divested Pharma Solutions. Each segment exhibited varied performance in 2025.

The Taste segment reported sales of $2.481 billion, marking a modest increase of 2% from $2.428 billion in 2024. The growth is attributed to volume increases across all business entities and the segment's inclusion in the core supplier lists of strategic customers.

In contrast, the Food Ingredients segment saw a decline in sales, dropping to $3.278 billion, down 3% from $3.365 billion in 2024. This decline was driven primarily by volume declines in the Protein Solutions category, despite growth in Inclusions.

On a positive note, the Health & Biosciences segment recorded sales of $2.283 billion, representing a 4% increase from $2.203 billion in 2024, driven by volume growth and price increases.

The Scent segment also experienced a slight increase, with sales rising to $2.479 billion, up 2% from $2.439 billion in 2024, supported by volume increases in Fragrance Compounds.

The Pharma Solutions segment faced a dramatic decline, reporting sales of $369 million, a staggering 65% drop from $1.049 billion in 2024. This significant decrease is attributed to the divestiture of the Pharma Solutions business unit, which resulted in an impairment charge of $1.153 billion for the Food Ingredients reporting unit.

IFF's revenue by geography highlighted a diverse but challenged market landscape, with all regions reporting declines in 2025.

This geographic distribution underscores the need for IFF to enhance its market strategies in these regions to reverse the declining trends.

The divestiture of the Pharma Solutions segment on May 1, 2025, and the Nitrocellulose business on May 9, 2025, were pivotal to IFF's strategic reorganization aimed at focusing on its core segments. However, this restructuring brought significant goodwill impairment charges, totaling $1.153 billion in 2025.

Research and Development (R&D) expenses rose to $694 million, reflecting increased investments in innovation. Meanwhile, Selling and Administrative (S&A) expenses decreased to $1.834 billion, attributed to lower incentive compensation related to the divestitures. Restructuring charges increased to $70 million, primarily due to severance costs linked to the IFF Productivity Program.

Despite a tumultuous year, IFF's focus on strategic growth in its core segments and operational efficiencies offers a pathway for recovery. As the company navigates through its restructuring phase, it aims to leverage its robust customer relationships and commitment to innovation to regain momentum in the flavors and fragrances market. The ongoing efforts to streamline operations and enhance profitability will be critical as IFF looks ahead to a more stable and prosperous future.

Investors and stakeholders will be keenly watching how IFF addresses these challenges while capitalizing on emerging market opportunities.